Actionable news
0
All posts from Actionable news
Actionable news in ESPR: Esperion Therapeutics, Inc.,

Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results

– Phase 3 Enrollment Progress Supports NDA Submissions for LDL-C Lowering Indications for Bempedoic
Acid / Ezetimibe Combination Pill and Bempedoic Acid by the First Quarter 2019 –
– Conference Call and Webcast on Tuesday, August 8, 2017 at 8:30 a.m. Eastern Time –

ANN ARBOR, Mich., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today provided bempedoic acid franchise development program updates, and financial results for the second quarter ended June 30, 2017. The company now expects to submit two New Drug Applications (NDAs) for LDL-C lowering indications for the bempedoic acid / ezetimibe combination pill and bempedoic acid by the first quarter of 2019.

Bempedoic Acid Global Pivotal Phase 3 Program Update

The ongoing Phase 3 program for bempedoic acid includes four global pivotal studies expected to enroll approximately 3,400 high CVD risk patients with hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), or who are high risk primary prevention...


More